Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) provides injectable drug administration solutions and services for pharmaceutical, biotechnology and generic drug customers. Its business includes elastomer-based packaging components such as stoppers, seals and plungers, nonglass containment technologies, auto-injectors and contract services for device manufacturing, assembly, packaging, validation, analytical testing and regulatory support.
News about West commonly covers quarterly results, revenue guidance, Proprietary Products and Contract Manufacturing performance, capacity additions for high-volume injectable therapies, and demand tied to biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. Other recurring developments include dividends, share repurchase authorizations, investor conference participation and governance or executive-transition updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
West Pharmaceutical Services (NYSE: WST) reported its Q1 2023 financial results on April 27, 2023. Net sales were $716.6 million, down 0.5% year-over-year, but organic sales increased by 2.3%. The diluted EPS dropped to $1.85, a decline of 19.2%. The company has raised its full-year net sales guidance to $2.965 billion to $2.990 billion, and adjusted-diluted EPS guidance to $7.50 to $7.65. A dividend of $0.19 per share was approved for Q3 2023, payable on August 2, 2023, to shareholders of record by July 26, 2023. Operational cash flow stood at $138.1 million, reflecting an 8.7% decrease, while free cash flow dropped 34.4% to $56.0 million. The firm anticipates continued growth despite a decline in COVID-19 related sales affecting its Biologics market unit.
West Pharmaceutical Services, a global leader in injectable solutions, announced the release date for its first-quarter 2023 financial results. The results will be published before the market opens on April 27, 2023. A conference call to discuss these results and future business expectations will be held at 9:00 a.m. Eastern Time on the same day. Investors can access a live audio-only webcast on the company’s Investor Relations website. To participate in the call, interested parties need to register in advance to receive dial-in details. A slide presentation will accompany the call and be available on the company's website. West Pharmaceutical reported $2.89 billion in net sales for 2022, marking its 100-year anniversary of innovation in healthcare.